Development of a Novel Diagnostic Modality for Upper Airway Obstruction via Integrating Dynamic Computed Tomography with Computational Fluid Dynamics
- Institution
- CHILDREN'S MERCY HOSP (KANSAS CITY, MO), MO
- Principal investigator
- John Patrick Dahl
- Funding
- $217K
- Duration
- 2024–2026
Moonbase score
Still being scored
Abstract
Project Summary/Abstract In the current state, clinical airway management decisions for patients with upper airway obstruction (UAO) are made based on a combination of qualitative imaging modalities, clinician experience, and a limited number of physiologic measures. Available diagnostics are inadequate and do not take into account the critical, dynamic nature of the respiratory cycle. Our goal is to create patient specific, quantitative, data driven metrics for stratifying the severity of UAO for use in clinical decision making. The upper airway (nares to larynx) consists of dynamic structures that change throughout the respiratory cycle. Robin Sequence (RS) is a potentially fatal congenital craniofacial condition characterized by undersized jaw, posteriorly displaced tongue, and resultant UAO. We chose to focus our initial efforts on RS patients due to the consistent clinical phenotype. Treatment options for patients with RS range from conservative measures such as prone positioning to invasive and morbid surgical procedures. Clinical decisions for RS patients with UAO are made based on static imaging studies obtained at a random phase in the respiratory cycle, subjective interpretation of awake flexible airway endoscopy, blood CO2 levels, polysomnograms, the treatment team’s clinical impression of the patient’s condition and the family’s goals of care. The factors contributing to clinical decisions are numerous but heavily influenced by multiple sources of bias based on the resources available at the treatment facility and the clinical training background/composition of the care team. There is a clear, unmet clinical need for a diagnostic modality that can both characterize the anatomic narrowing and quantify UAO. We plan to address this need by integrating computational fluid dynamic (CFD) modeling with a novel computed tomography protocol that captures dynamic airway changes throughout the respiratory cycle (4D-CT). In the future state, we anticipate the 4D-CT/CFD-based diagnostic modality will be used to define the anatomic location(s) of dynamic UAO and quantify the severity of the UAO at each level. This information will be used, in part, to determine which treatment is optimal for individual patients. As part of this work, we will define specific CFD and clinical outcome measures that are most critical to UAO treatment decisions. Preliminary data shows that the CFD analysis output (breathing resistance, energy loss, peak velocity) can identify the level(s) and severity of airway compromise. The aims of this proposal are to further develop, refine and validate the technique for integrating 4D-CT acquisition with CFD analysis to ultimately inform treatment decisions in infants with UAO. By combining 4D-CT imaging with CFD techniques, we aim to create a simple, accurate, quantitative, patient specific diagnostic modality that will address the current gap. Once validated in RS patients this diagnostic approach could be applied to numerous other conditions impacted by UAO including obstructive sleep apnea and laryngomalacia.
LOADING MOONBASE SCORE
Questions for CHILDREN'S MERCY HOSP (KANSAS CITY, MO)
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Children'S Mercy Hosp (Kansas City, MO)Not yet scored
An integrative approach to identify biomarkers and investigate mechanisms of adverse drug reactions
Jennifer Lynn Goldman · $434K · 2025–2030
- NIH · Children'S Mercy Hosp (Kansas City, MO)Not yet scored
Simultaneous ROS production and DDR inhibition to trigger p53 synthetic lethality
Tomoo Iwakuma · $560K · 2025–2030
- NIH · Children'S Mercy Hosp (Kansas City, MO)Not yet scored
Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children with Dystonia and Cerebral Palsy
Rose Nicole Gelineau-Morel · $164K · 2025–2029